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WILLINGNESS TO PAY STUDIES
WP1
WILLINGNESS TO PAY FOR PHARMACIST-
PROVIDED MENOPAUSE AND HORMONE
REPLACEMENT THERAPY CONSULTATIONS
Branvold AE, Barner J, Vincze G
University of Texas at Austin, Austin,TX, USA
Pharmacists are accepting an increasing role in patient
care by providing a variety of pharmaceutical care ser-
vices. As third party payers have been reluctant to reim-
burse pharmaceutical care services, pharmacists rely on
out-of-pocket payment from patients. It would be bene-
ﬁcial to pharmacists to understand the magnitude of the
amount and factors that inﬂuence patients’ willingness to
pay (WTP) for their services. OBJECTIVES: The objec-
tives of this study were to 1) determine the amount of
women would be willing to pay (WTP) for a consultation
provided by the pharmacist, and 2) determine the rela-
tionship between WTP and “importance of resolving
menopausal symptoms,” “satisfaction with physician ser-
vices,” “patients’ perceptions of pharmacists’ services”
and “income.” METHODS: Five hundred adult women
using hormone replacement therapy (HRT) to treat
menopause were recruited by their pharmacists. The WTP
amount was assessed for four scenarios (i.e., 50% and
100% improvement in symptoms after a half-hour initial
and a half-hour follow-up visit, respectively). RESULTS:
Two hundred and three patients returned the survey via
mail resulting in a 41% response rate. Respondents were
willing to pay $42.07 ± $30.27 (median = $40) and
$65.60 ± $42.80 (median = $40) (for 50% and 100%
improvement, respectively) per initial consultation; and
$33.68 ± $26.60 (median = $20) and $51.40 ± $36.61
(median = $40) (50% and 100% improvement, respec-
tively) per follow-up consultation. Regression models
revealed that patients’ income level and their perceptions
of pharmacists’ services were positively and signiﬁcantly
(p < .05) associated with WTP across all of the four sce-
narios. CONCLUSIONS: Women treated with HRT for
menopausal symptoms were willing to pay for pharma-
cist-provided counseling services and the WTP amounts
increased with more positive perceptions of these services
and with higher income level. These results might be
encouraging for pharmacists who are considering pro-
viding consultation services to patients experiencing
menopausal symptoms.
WP2
ESTIMATING WILLINGNESS TO PAY FOR DRUGS
TO TREAT ADHD—A CONTINGENT VALUATION
STUDY IN STUDENTS
De Ridder A, De Graeve D
University of Antwerp, Antwerpen, Belgium
OBJECTIVES: New drugs with extended release are
being developed to treat patients with ADHD. Instead of
taking two to three pills a day, a one-time daily intake
becomes possible with a more consistent working proﬁle
during the day. The current study tries to ﬁnd 1) the WTP
for this improved release as compared to the standard
drug and 2) whether the order in which the drugs are pre-
sented is of inﬂuence. METHODS: A pre-tested ques-
tionnaire was administered to 114 ﬁnal-year economics
students from the University of Antwerp. In order for stu-
dents to have a binding income constraint, they were told
to consider themselves as the head of the household with
a speciﬁed income. Income was varied in the sample.
After presenting information on the disease and on the
effects of the drug, WTP was elicited using the payment
card method. Respondents were allowed to answer yes or
no with different degrees of certainty. A split sample was
used to test the hypothesis, which states that the order in
which the drugs are presented is imperative. RESULTS:
The average willingness to pay per month amounts to
€57.34 certainly and €74.29 probably for the standard
drug and to €81.95 certainly and €95.12 probably for the
extended release. The difference between the two drugs
is statistically signiﬁcant (Wilcoxon signed rank test). Stu-
dents state a higher WTP for the new drug if the current
therapy is presented ﬁrst (Mann Whitney U test). CON-
CLUSIONS: The current study brought some further evi-
dence on the validity of the CV method to ﬁnd out WTP.
It showed that students can be used to elicit WTP for
drugs when given a ﬁctitious income. The study also
showed that WTP for a new drug differs if ﬁrst given
information on an old drug compared to giving the infor-
mation in the second place. This is related to the embed-
ding effect found in other studies and hampers the validity
of the method.
WP3
WILLINGNESS TO PAY FOR A PHARMACIST
INTERVENTION PROGRAM AMONG NON-
COMPLIANT DYSLIPIDEMIA PATIENTS
Ali F, Laurin MY, Lariviere C,Tremblay D, Cloutier D
Pﬁzer Canada Inc, Kirkland, QC, Canada
OBJECTIVE: Through the willingness to pay method,
evaluate the value of a pharmacist intervention program
focused on patient education, life-style changes and com-
pliance to lipid-lowering therapy. METHODS: Patients
non-compliant to their lipid-lowering therapy were asked
to participate in a six-month program. At the beginning
and once during the 6 months, patients received a 30-
minute consultation with the pharmacist where they were
educated on their disease, the importance of compliance
to therapy and the need for life-style changes. In addition,
pharmacists phoned the patients every two months to re-
emphasize the importance of treatment compliance and
life-style changes. At the end of the six-month program,
patients were asked to complete a willingness to pay ques-
tionnaire to assess how much they valued such a program
based on their experience. The willingness to pay had a
value range of $0 to $55 CAN. Non-parametric tests were
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used to analyze the compliance and serum lipid data.
Patients served as their own controls (before-after design).
RESULTS: One hundred and forty-nine patients par-
ticipated in the program (n = 149). At the end of the
program, there was a 15.3% increase in the number of
compliant patients and an improvement of 21.7%
(pfÿ.001) in the average number of days to prescription
renewal. Concurrently, levels of total cholesterol, triglyc-
erides and low-density lipoprotein (LDL) cholesterol,
were reduced by 6% (pfÿ.001), 16.2% (pfÿ.01), and
8.5% (pfÿ.01) respectively. Patients were, on average,
willing to pay $34.50 CAN (std = 13.7) for this program.
More than 61% of patients were willing to pay $35 to
$55 CAN and only one patient was not willing to pay
anything to receive such a program. CONCLUSION: On
average, patients were willing to pay around $35 CAN
for a pharmacist interventional program that improved
their compliance to lipid-lowering therapy and bettered
their serum lipid proﬁle.
